Details for Patent: 7,713,995
✉ Email this page to a colleague
Title: | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Abstract: | Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. |
Inventor(s): | Weiner; David M. (San Diego, CA), Davis; Robert E. (San Diego, CA), Brann; Mark R. (Rye, NH), Nash; Norman (San Diego, CA), Andersson; Carl-Magnus A. (Hjarup, SE), Uldam; Allan K. (Ballerup, DK) |
Assignee: | Acadia Pharmaceuticals, Inc. (San Diego, CA) |
Filing Date: | May 03, 2006 |
Application Number: | 11/416,594 |
Claims: | 1. A method of treating a sleep disorder, comprising administering to a subject having a sleep disorder a therapeutically effective amount of the compound of formula (I): ##STR00010## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the sleep disorder is associated with dysfunction of a monoamine receptor. 3. The method of claim 1, wherein the sleep disorder is associated with activation of a monoamine receptor. 4. The method of claim 1, wherein the sleep disorder is associated with increased activity of a monoamine receptor. 5. The method of claim 2, wherein the monoamine receptor is a serotonin receptor. 6. The method of claim 5, wherein the serotonin receptor is the 5-HT2A subclass. 7. The method of claim 5, wherein the serotonin receptor is in central nervous system. 8. The method of claim 1, wherein the subject is a human. 9. The method of claim 1, wherein the salt is a tartrate salt. 10. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 0.001 mg to about 50 mg. 11. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 10 mg. 12. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 10 mg. 13. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 25 mg. 14. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 50 mg. 15. The method of claim 1, wherein the salt is a hydrochloride salt. |